Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti‐CD40 antibody (SGN‐40) in rodents and non‐human primates
Authors:
- 1 August 2006
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 148 (8) , 1116-1123
Abstract
Cell‐surface expression of CD40 in B‐cell malignancies and multiple solid tumors has raised interest in its potential use as a target for antibody‐based cancer therapy. SGN‐40, a humanized monoclonal anti‐CD40 antibody, mediates antibody‐dependent cytotoxicity and inhibits B‐cell tumor growth in vitro, properties of interest for the treatment of cancers, and is currently in Phase I clinical trials for B‐cell malignancies. In this study, we determined in vivo activity and pharmacokinetics properties of SGN‐40. Effect of SGN‐40 in xenograft model of CD40‐expressing B‐cell lymphoma in severe‐combined immune deficiency mice and its in vivo pharmacokinetics properties in normal mice, rats and cynomolgus monkeys were studied. Treatment with SGN‐40 significantly increased the survival of mice xenografted with human B‐cell lymphoma cell line. SGN‐40 exhibited nearly 100% bioavailability in mice and it cleared faster when given at a low dose. In monkeys, clearance of SGN‐40 was also much faster at low dose, suggesting nonlinear pharmacokinetics in these species. In rats, however, SGN‐40 clearance at all tested doses was similar, suggesting that pharmacokinetics were linear in this dose range in rats. Administration of SGN‐40 to monkeys also produced marked, dose‐dependent, and persistent depletion of peripheral CD20+ B lymphocytes. Data presented in this report suggest that SGN‐40 is active in in vivo, and based upon interspecies scaling, SGN‐40 clearance in humans is predicted to be similar to observed SGN‐40 clearance in monkeys. These data suggest that SGN‐40 has appropriate pharmacokinetic properties that support its clinical use. British Journal of Pharmacology (2006) 148, 1116–1123. doi:10.1038/sj.bjp.0706828Keywords
This publication has 32 references indexed in Scilit:
- Preclinical Antilymphoma Activity of a Humanized Anti-CD40 Monoclonal Antibody, SGN-40Cancer Research, 2005
- The role of the CD40 pathway in the pathogenesis and treatment of cancerCurrent Opinion in Pharmacology, 2004
- Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responsesNature Medicine, 2004
- Signalling pathways of the TNF superfamily: a double-edged swordNature Reviews Immunology, 2003
- Prospects for CD40-directed experimental therapy of human cancerCancer Gene Therapy, 2002
- CD40 AND CD154 IN CELL-MEDIATED IMMUNITYAnnual Review of Immunology, 1998
- Role of the CD40 and CD95 (APO‐1/Fas) antigens in the apoptosis of human B‐cell malignanciesBritish Journal of Haematology, 1997
- A novel function of CD40: induction of cell death in transformed cells.Journal of Experimental Medicine, 1996
- The CD40 Antigen and its LigandAnnual Review of Immunology, 1994
- Interspecies scaling and comparisons in drug development and toxicokineticsXenobiotica, 1990